DK2344471T3 - 7-piperidinalkyl-3,4-dihydroquinolon-derivat - Google Patents

7-piperidinalkyl-3,4-dihydroquinolon-derivat

Info

Publication number: DK2344471T3
Authority: DK; Denmark
Prior art keywords: piperidinealkyl; dihydroquinolone; derivative; dihydroquinolone derivative
Prior art date: 2008-10-02

Application number

DK09817928.6T

Other languages

English (en)

Inventor

Kosuke Kanuma

Naoki Miyakoshi

Madoka Kawamura

Tsuyoshi Shibata

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2009-09-30

Publication date

2013-10-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-30 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2013-10-07 Application granted granted Critical

2013-10-07 Publication of DK2344471T3 publication Critical patent/DK2344471T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Addiction (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK09817928.6T 2008-10-02 2009-09-30 7-piperidinalkyl-3,4-dihydroquinolon-derivat DK2344471T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008257072		2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number	Publication Date
DK2344471T3 true DK2344471T3 (da)	2013-10-07

Family

ID=42073652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09817928.6T DK2344471T3 (da)	2008-10-02	2009-09-30	7-piperidinalkyl-3,4-dihydroquinolon-derivat

Country Status (29)

Country	Link
US (1)	US8461182B2 (da)
EP (1)	EP2344471B1 (da)
JP (1)	JP5541279B2 (da)
KR (1)	KR20110067026A (da)
CN (1)	CN102239159B (da)
AR (1)	AR073727A1 (da)
AU (1)	AU2009300607C1 (da)
BR (1)	BRPI0925343A2 (da)
CA (1)	CA2739513A1 (da)
CL (1)	CL2011000734A1 (da)
CO (1)	CO6321164A2 (da)
CY (1)	CY1114165T1 (da)
DK (1)	DK2344471T3 (da)
ES (1)	ES2424393T3 (da)
HK (1)	HK1159622A1 (da)
HR (1)	HRP20130728T1 (da)
IL (1)	IL212070A (da)
MX (1)	MX2011003500A (da)
MY (1)	MY154337A (da)
NZ (1)	NZ592008A (da)
PE (1)	PE20110410A1 (da)
PL (1)	PL2344471T3 (da)
PT (1)	PT2344471E (da)
RS (1)	RS52964B (da)
RU (1)	RU2498981C2 (da)
SI (1)	SI2344471T1 (da)
UA (1)	UA105187C2 (da)
WO (1)	WO2010038901A1 (da)
ZA (1)	ZA201102315B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011219467A (ja) *	2010-03-26	2011-11-04	Taisho Pharmaceutical Co Ltd	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
EP2638014B1 (en)	2010-11-08	2017-01-04	Lycera Corporation	N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
CA2872014A1 (en)	2012-05-08	2013-11-14	Lycera Corporation	Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
AU2013259737A1 (en)	2012-05-08	2014-10-02	Lycera Corporation	Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
KR101717872B1 (ko) *	2013-03-12	2017-03-17	(주)바이오팜솔루션즈	소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
US9663502B2 (en)	2013-12-20	2017-05-30	Lycera Corporation	2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en)	2013-12-20	2017-10-10	Lycera Corporation	Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9809561B2 (en)	2013-12-20	2017-11-07	Merck Sharp & Dohme Corp.	Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US10532088B2 (en)	2014-02-27	2020-01-14	Lycera Corporation	Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
US10189777B2 (en)	2014-05-05	2019-01-29	Lycera Corporation	Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
EP3140291A4 (en)	2014-05-05	2018-01-10	Lycera Corporation	Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2016219183B2 (en)	2015-02-11	2020-06-11	Merck Sharp & Dohme Corp.	Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10421751B2 (en)	2015-05-05	2019-09-24	Lycera Corporation	Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2016201225A1 (en)	2015-06-11	2016-12-15	Lycera Corporation	Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3368535B1 (en)	2015-10-27	2020-12-02	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
RU2018117503A (ru)	2015-10-27	2019-11-28	Мерк Шарп И Доум Корп.	ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
WO2017075178A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
NZ746311A (en) *	2016-02-12	2022-08-26	Cytokinetics Inc	Tetrahydroisoquinoline derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04116B1 (et) *	1995-09-15	2003-08-15	Synthlabo	Kinolin-2(1H)-ooni derivaadid kui serotoniini antagonistid
WO2003028641A2 (en) *	2001-10-01	2003-04-10	Taisho Pharmaceutical Co., Ltd.	Mch receptor antagonists
EP1447402A4 (en) *	2001-10-25	2005-01-19		quinoline
WO2004087680A1 (en) *	2003-03-31	2004-10-14	Taisho Pharmaceutical Co., Ltd.	Novel quinazoline derivatives and methods of treatment related to the use thereof
US20050197350A1 (en) *	2003-03-31	2005-09-08	Taisho Pharmaceutical Co., Ltd.	Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
ZA200607639B (en) *	2004-03-30	2008-05-28	Taisho Pharmaceutical Co Ltd	Pyrimidine derivatives and methods of treatment related to the use thereof
US20080090863A1 (en) *	2004-09-30	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
JPWO2008044632A1 (ja) *	2006-10-06	2010-02-12	大正製薬株式会社	１−ナフチルアルキルピペリジン誘導体

2009
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 RS RS20130370A patent/RS52964B/en unknown
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en active Application Filing
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Ceased
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
2012
- 2012-01-04 HK HK12100046.0A patent/HK1159622A1/xx not_active IP Right Cessation
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown
- 2013-08-01 HR HRP20130728AT patent/HRP20130728T1/hr unknown

Also Published As

Publication number	Publication date
CN102239159A (zh)	2011-11-09
AU2009300607C1 (en)	2014-08-07
JP5541279B2 (ja)	2014-07-09
ES2424393T3 (es)	2013-10-01
IL212070A0 (en)	2011-06-30
NZ592008A (en)	2011-12-22
AU2009300607A1 (en)	2010-04-08
CN102239159B (zh)	2014-06-25
AU2009300607B2 (en)	2014-02-27
KR20110067026A (ko)	2011-06-20
UA105187C2 (uk)	2014-04-25
PL2344471T3 (pl)	2013-12-31
PE20110410A1 (es)	2011-07-02
RU2498981C2 (ru)	2013-11-20
MY154337A (en)	2015-05-29
WO2010038901A1 (en)	2010-04-08
JP2012504549A (ja)	2012-02-23
HRP20130728T1 (en)	2013-10-11
EP2344471A1 (en)	2011-07-20
CA2739513A1 (en)	2010-04-08
EP2344471A4 (en)	2012-05-30
BRPI0925343A2 (pt)	2015-07-28
EP2344471B1 (en)	2013-07-24
CL2011000734A1 (es)	2011-09-23
US20110178304A1 (en)	2011-07-21
ZA201102315B (en)	2012-06-27
CO6321164A2 (es)	2011-09-20
AR073727A1 (es)	2010-11-24
MX2011003500A (es)	2011-05-02
IL212070A (en)	2014-07-31
US8461182B2 (en)	2013-06-11
RU2011117161A (ru)	2012-11-10
PT2344471E (pt)	2013-08-01
SI2344471T1 (sl)	2013-11-29
RS52964B (en)	2014-02-28
HK1159622A1 (en)	2012-08-03
CY1114165T1 (el)	2016-08-31

Publication	Publication Date	Title
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINDERIVAT
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
DK3444343T3 (da)	2021-01-18	Polypeptider
FI20085383A0 (fi)	2008-04-29	Matonpesulaitteisto
EP2336132A4 (en)	2012-03-21	MORPHOLINPURINDERIVAT
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
ATE545635T1 (de)	2012-03-15	Substituierte n-oxidpyrazinderivate
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DK2442870T3 (da)	2014-06-30	Pyrazinooxazepin-derivater.
ATE534634T1 (de)	2011-12-15	2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0912716A2 (pt)	2015-10-13	composto.
EP2376295A4 (en)	2012-09-05	LATERAL WALL SHEAR DECOUPLING LAYER
BRPI0909425A2 (pt)	2015-12-01	derivado de hidroxiquinoxalinacarboxamida
EP2256105A4 (en)	2011-09-14	Novel tetrahydroisoquinoline derivative
EP2248811A4 (en)	2011-08-03	2-OXOCHROMEN DERIVATIVE
IT1396642B1 (it)	2012-12-14	Statore.
ATE519751T1 (de)	2011-08-15	Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate